abiraterone has been researched along with Lymph Node Metastasis in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 3 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Balestra, A; Droz-Perroteau, C; Fizazi, K; Fourrier-Reglat, A; Guiard, E; Joly, F; Jove, J; Lacueille, C; Lamarque, S; Moore, N; Oudard, S; Rouyer, M; Tubach, F | 1 |
| Ahmed, ME; Andrews, JR; Bryce, AH; Karnes, RJ; Kwon, E | 1 |
| Hu, S; Liu, C; Song, S; Su, H; Wang, B; Xu, X; Ye, D; Zhang, Y; Zhu, Y | 1 |
| Amaravadi, R; Black, TA; Buckingham, TH; Calara-Nielsen, K; Carpenter, EL; Cherkas, Y; Foulk, B; Gross, S; Haas, NB; He, M; Jones, JO; LaRiviere, MJ; Long, Q; Majmundar, KJ; Min, EJ; Pal, SK; Patel, J; Savitch, SL; Smirnov, D; Vaughn, DJ; Wellen, KE; Yee, SS | 1 |
| Agrawal, M; Almeida, F; Brown, A; Dicker, AP; Fernandez, DC; Garcia, JA; Gratt, J; Iagaru, A; Lutzky, J; Morris, MJ; Petrenciuc, O; Sartor, O; Shore, ND; Smith, MR; Sweeney, C; Vogelzang, NJ; Wong, YN | 1 |
| Baldauf, S; Bartsch, G; Borgmann, H; Brandt, MP; Dotzauer, R; Frees, S; Haferkamp, A; Jäger, W; Neisius, A; Schneider, M; Thomas, C; Tsaur, I | 1 |
| Böker, A; Geith, A; Gschwend, JE; Kuczyk, M; Merseburger, AS; Retz, M; Schmid, SC; Seitz, AK; Tauber, R; von Klot, C | 1 |
| Djavan, B; Farr, A; Herout, R; Margreiter, M; Tosev, G | 1 |
| Shah, BK; Shrestha, S | 1 |
1 trial(s) available for abiraterone and Lymph Node Metastasis
| Article | Year |
|---|---|
Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms; Nitriles; Phenylthiohydantoin; Prognosis; Radium; Survival Rate | 2018 |
8 other study(ies) available for abiraterone and Lymph Node Metastasis
| Article | Year |
|---|---|
Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prednisone; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2019 |
Systemic treatment for metastatic castrate resistant prostate cancer: Does seqence matter?
Topics: Androstenes; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Neoplasms; Docetaxel; Drug Administration Schedule; Humans; Kallikreins; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate | 2020 |
Preliminary results of targeted prostate-specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androstenes; Antigens, Surface; Antineoplastic Agents, Hormonal; Bone Neoplasms; Glutamate Carboxypeptidase II; Humans; Lymphatic Metastasis; Male; Middle Aged; Organotechnetium Compounds; Progression-Free Survival; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome | 2020 |
Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplastic Cells, Circulating; Nitriles; Phenylthiohydantoin; Prednisone; Prognosis; Prospective Studies; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Survival Rate; Transcriptome | 2021 |
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Topics: Aged; Androstenes; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease-Free Survival; Docetaxel; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms, Castration-Resistant; Retreatment; Retrospective Studies; Survival Rate; Taxoids | 2018 |
Enzalutamide after docetaxel and abiraterone therapy in metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androstenes; Androstenols; Antineoplastic Agents; Benzamides; Bone Neoplasms; Compassionate Use Trials; Disease-Free Survival; Docetaxel; Humans; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nitriles; Phenylthiohydantoin; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Failure | 2014 |
New findings in bladder and prostate cancer: highlights from the 26th annual congress of the European Association of Urology, March 18-22, 2011, Vienna, Austria.
Topics: Androstenes; Androstenols; Biomarkers; Humans; Lymph Node Excision; Lymphatic Metastasis; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Pelvis; Prostatectomy; Prostatic Neoplasms; Radioimmunotherapy; Urinary Bladder Neoplasms | 2011 |
Durable complete remission with abiraterone in castration resistant metastatic prostate cancer.
Topics: Adenocarcinoma; Androstenes; Androstenols; Antineoplastic Agents, Hormonal; Castration; Humans; Lymphatic Metastasis; Male; Middle Aged; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction | 2013 |